Percutaneous interventions in radiation-associated coronary in-stent restenosis

Cardiovasc Intervent Radiol. 2003 Mar-Apr;26(2):154-7. doi: 10.1007/s00270-002-2644-z. Epub 2003 Mar 18.

Abstract

This study was performed to evaluate the outcome of percutaneous revascularization in "edge restenoses" developing after radioactive stent implantation in de novo and in-stent lesions. Twenty-one consecutive patients undergoing target lesion revascularization (TLR) at any follow-up after phosphorus-32 radioactive stent implantation were included in this study. We assessed the incidence of death, myocardial infarction, repeated TLR and recurrent angina over the following 18 months. After 6 months, TLR rate was 28.6%, and no stent thromboses, deaths or Q-wave myocardial infarctions occurred. Among the patients with TLR there were significantly more subjects who had received a radioactive stent in a previous in-stent restenosis (66.7% vs. 0% in patients without second restenosis; P <0.001), or who had received two radioactive stents (83.3% vs. 33.3%; P = 0.038). After 18 months, TLR rate was 33.3%, and two patients (9.5%) had died. Restenosis after intravascular radiotherapy can be safely treated by percutaneous interventional techniques, yielding an acceptable clinical result within 18 months.

Publication types

  • Comparative Study
  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Angioplasty, Balloon, Coronary
  • Arteries / pathology
  • Arteries / radiation effects
  • Arteries / surgery
  • Austria
  • Blood Vessel Prosthesis Implantation
  • Coated Materials, Biocompatible / adverse effects
  • Coated Materials, Biocompatible / therapeutic use
  • Coronary Restenosis / etiology*
  • Coronary Restenosis / therapy
  • Coronary Vessels / pathology
  • Coronary Vessels / radiation effects
  • Coronary Vessels / surgery
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Phosphorus Radioisotopes / adverse effects
  • Phosphorus Radioisotopes / therapeutic use
  • Radiation*
  • Radiopharmaceuticals / adverse effects
  • Radiopharmaceuticals / therapeutic use
  • Reoperation
  • Stents*
  • Treatment Outcome

Substances

  • Coated Materials, Biocompatible
  • Phosphorus Radioisotopes
  • Radiopharmaceuticals